HRMY (Harmony Biosciences Holdings) Growth Rank: 10 (As of Aug. 27, 2026) — 11% Above Median

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

HRMY Harmony Biosciences Holdings Inc HRMY
95 GF Score
Price $39.61
GF Value $46.94
Valuation Modestly Undervalued
! 2 Warning Signs
View Full Analysis

What is Harmony Biosciences Holdings Growth Rank?

Harmony Biosciences Holdings HRMY +1.89% 95 Growth Rank is 10 as of Aug. 27, 2026, which is 11% above its 10-year median of 9.00. GuruFocus rates HRMY with a GF Score™ of 95/100 and a GF Value™ of $46.94 (Modestly Undervalued). The stock has 2 warning signs investors should review.

Harmony Biosciences Holdings has the Growth Rank of 10.

GuruFocus Growth Rank measures the growth of a company in terms of its revenue and profitability, rated on a scale from 1 to 10. Historically, the companies with the highest growth ranks performed the best over the long term. It is calculated using the following criteria:

1. 5-year revenue growth rate, the higher, the better.
2. 3-year revenue growth rate, the higher, the better.
3. 5-year EBITDA growth rate, the higher, the better.
4. The predictability of 5-year revenue. The most consistent it is, the higher the rank.

A higher score reflects a greater ability to drive business growth, with companies considered to have strong and sustainable expansion potential. Conversely, a lower score indicates challenges in achieving consistent growth and scalability.

GuruFocus found that the Growth Rank is the second of the two most-sensitive parameters among the five parameters checked. Please click GF Score to see more details on GF Score's 5 Key Aspects of Analysis.

Please note that we are using the five-year EBITDA growth rate as a parameter, so the company needs to have had positive growth over that time. The reason we use EBITDA instead of earnings per share is that with EBITDA, we can rank a lot more companies since a company may have positive EBITDA but negative EPS. Since we are looking at the growth here, EBITDA gives us a pretty clear picture about the growth in the company's business operations.

Harmony Biosciences Holdings Growth Rank Related Terms

HRMY vs SION, URGN, PVLA: Growth Rank Comparison

For the Biotechnology subindustry, Harmony Biosciences Holdings's Growth Rank, along with its competitors' market caps and Growth Rank data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Harmony Biosciences Holdings Growth Rank vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Harmony Biosciences Holdings's Growth Rank distribution charts can be found below:

* The bar in red indicates where Harmony Biosciences Holdings's Growth Rank falls into.


HRMY
95GF Score
Harmony Biosciences Holdings Inc HRMY
Growth Rank is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
Frequently Asked Questions Learn more about Growth Rank →
What does a Growth Rank of 10 mean?
Harmony Biosciences Holdings (HRMY) has a Growth Rank of 10 as of Aug. 27, 2026. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Harmony Biosciences Holdings and its competitors. This is 11% above median its historical median of 9.00. Over the past decade, Harmony Biosciences Holdings' Growth Rank has ranged from 8.00 to 10.00.
Is Harmony Biosciences Holdings' Growth Rank too high?
Harmony Biosciences Holdings' current Growth Rank of 10 is 11% above median its 10-year median of 9.00. Over the past 10 years, this metric has ranged from a low of 8.00 to a high of 10.00. Overall, Harmony Biosciences Holdings has a GF Score™ of 95/100 and is considered Modestly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Harmony Biosciences Holdings' Growth Rank compare to SION and URGN?
Harmony Biosciences Holdings' Growth Rank of 10 can be compared against companies in the Biotechnology industry. Historically, Harmony Biosciences Holdings' own Growth Rank has ranged from 8.00 to 10.00 over the past decade. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Growth Rank for a Biotechnology company?
A good Growth Rank depends on the Biotechnology industry context. However, Growth Rank should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Growth Rank mean?
A high Growth Rank can signal that a stock is expensive relative to its fundamentals. Growth Rank measures the growth of a company in terms of its revenue and profitability. View historical data on Harmony Biosciences Holdings and its competitors. Harmony Biosciences Holdings's current Growth Rank is 10, which is 11% above median its own 10-year median of 9.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Harmony Biosciences Holdings stock overvalued right now?
Based on GuruFocus' analysis, Harmony Biosciences Holdings (HRMY) is currently considered Modestly Undervalued. The stock's GF Value™ is $46.94, compared to a current price of $39.61 — trading 15.6% below its estimated fair value. The current Growth Rank is 10, which is 11% above median its 10-year median of 9.00. Harmony Biosciences Holdings' overall GF Score™ is 95/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Growth Rank calculated?
Growth Rank is calculated from a company's financial statements. For Harmony Biosciences Holdings (HRMY), the current Growth Rank is 10 as of Aug. 27, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Harmony Biosciences Holdings (HRMY) Overvalued in 2026?

Based on GuruFocus' analysis, Harmony Biosciences Holdings stock appears to be undervalued. The current stock price of $39.61 is trading 15.6% below its estimated GF Value™ of $46.94. GuruFocus considers Harmony Biosciences Holdings to be Modestly Undervalued.

Key valuation signals for HRMY:

  • Growth Rank: 10 (11% above median its 10-year median of 9.00)
  • GF Value™: $46.94 vs. price of $39.61 (15.6% below fair value)
  • GF Score™: 95/100 with 2 warning signs

No single metric tells the full story. See the HRMY stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Harmony Biosciences Holdings Business Description

Address 630 W. Germantown Pike, Suite 215, Plymouth Meeting, PA, USA, 19462
Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.
95GF Score

Get the complete analysis for HRMY

Growth Rank is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$39.61
Price
$46.94
GF Value